toggle visibility Search & Display Options

Select All    Deselect All
 |   | 
  Record Links
Author Meyer, K.A.; Arduino, J.M.; Santanello, N.C.; Knorr, B.A.; Bisgaard, H. url  openurl
  Title Response to montelukast among subgroups of children aged 2 to 14 years with asthma Type
  Year (down) 2003 Publication The Journal of Allergy and Clinical Immunology Abbreviated Journal J Allergy Clin Immunol  
  Volume 111 Issue 4 Pages 757-762  
  Keywords Acetates/*therapeutic use; Adolescent; Asthma/*drug therapy/physiopathology; Child; Child, Preschool; Double-Blind Method; Female; Forced Expiratory Volume/drug effects; Humans; Leukotriene Antagonists/*therapeutic use; Male; Quinolines/*therapeutic use  
  Abstract BACKGROUND: Determining who responds to asthma therapies, particularly leukotriene modifiers, continues to be explored. OBJECTIVE: We sought to identify patient characteristics predictive of response to montelukast. METHODS: We used data from 2 clinical trials in which children with asthma received either montelukast or placebo. Symptoms, beta-agonist use, and unanticipated health resource use caused by asthma were recorded in validated daily diaries for children 2 to 5 (n = 689) and 6 to 14 (n = 336) years old. We defined primary end points of days without asthma in 2- to 5-year-old patients (24 hours without symptoms, beta-agonist use, or asthma attack) and change in percent predicted FEV(1) in 6- to 14-year-old children. Asthma attack was defined by the use of rescue oral corticosteroids or by an unscheduled visit to a medical provider. Patients were grouped according to baseline characteristics, such as family history of asthma, personal history of allergy, frequency of asthma symptoms, eosinophilia, and concomitant use of inhaled corticosteroids or cromolyn. We examined the stratum-specific effects of montelukast on the percentage of days without asthma, change in percent predicted FEV(1), asthma attack, and a variety of secondary symptom and FEV(1) end points. RESULTS: We did not identify characteristics that predicted response to montelukast in either preschool or 6- to 14-year-old children. These findings were consistent across all symptom and FEV(1) outcomes. There was also no differential response to montelukast in either age group when asthma attack was the outcome. CONCLUSION: The patient characteristics studied do not appear to provide an indication of who will benefit most from treatment with montelukast.  
  Address Department of Pulmonary-Immunology, Merck Research Laboratories, Rahway, USA  
  Corporate Author Thesis  
  Impact Factor 11,476 First Author Meyer, K.A. Editor  
  Language English Summary Language Original Title  
  Series Editor Series Title Abbreviated Series Title  
  Series Volume Series Issue Senior Author Bisgaard, H.  
  ISSN 0091-6749 ISBN Medium  
  Area Expedition Conference  
  Notes PMID:12704354 Approved no  
  Call Number Serial 163  
Permanent link to this record
Select All    Deselect All
 |   | 

Save Citations:
Export Records: